Literature DB >> 31005599

Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells.

David H M Steffin1, Helen E Heslop2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31005599      PMCID： PMC6520459          DOI： 10.1016/j.ymthe.2019.04.007

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  10 in total

1.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Authors:  Chrystal U Louis; Barbara Savoldo; Gianpietro Dotti; Martin Pule; Eric Yvon; G Doug Myers; Claudia Rossig; Heidi V Russell; Oumar Diouf; Enli Liu; Hao Liu; Meng-Fen Wu; Adrian P Gee; Zhuyong Mei; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Blood       Date:  2011-10-07       Impact factor: 22.113

2.  Next Steps in the CAR Journey of a Thousand Miles.

Authors:  Malcolm K Brenner
Journal:  Mol Ther       Date:  2017-09-20       Impact factor: 11.454

Review 3.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

4.  CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Authors:  Andras Heczey; Chrystal U Louis; Barbara Savoldo; Olga Dakhova; April Durett; Bambi Grilley; Hao Liu; Mengfeng F Wu; Zhuyong Mei; Adrian Gee; Birju Mehta; Huimin Zhang; Nadia Mahmood; Haruko Tashiro; Helen E Heslop; Gianpietro Dotti; Cliona M Rooney; Malcolm K Brenner
Journal:  Mol Ther       Date:  2017-06-09       Impact factor: 11.454

5.  EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Stefanie Lesch; Sebastian Balbach; Claudia Göttlich; Johanna Kühnemundt; Jan-Henrik Mikesch; Sonja Schelhaas; Silke Jamitzky; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Kornelius Kerl; Holger N Lode; Nikolai Siebert; Ingo Müller; Heike Walles; Wolfgang Hartmann; Claudia Rossig
Journal:  Mol Ther       Date:  2019-02-23       Impact factor: 11.454

Review 6.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

7.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

8.  Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.

Authors:  Thomas Shum; Bilal Omer; Haruko Tashiro; Robert L Kruse; Dimitrios L Wagner; Kathan Parikh; Zhongzhen Yi; Tim Sauer; Daofeng Liu; Robin Parihar; Paul Castillo; Hao Liu; Malcolm K Brenner; Leonid S Metelitsa; Stephen Gottschalk; Cliona M Rooney
Journal:  Cancer Discov       Date:  2017-08-22       Impact factor: 39.397

9.  HDAC inhibitors enhance the immunotherapy response of melanoma cells.

Authors:  Laurence Booth; Jane L Roberts; Andrew Poklepovic; John Kirkwood; Paul Dent
Journal:  Oncotarget       Date:  2017-05-17

Review 10.  Making CAR T Cells a Solid Option for Solid Tumors.

Authors:  Andrea Schmidts; Marcela V Maus
Journal:  Front Immunol       Date:  2018-11-08       Impact factor: 7.561
  10 in total
  1 in total

Review 1.  A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.

Authors:  Zili Lin; Ziyi Wu; Wei Luo
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.